Overall, the high affinity and inhibitory action of zinc(ii) trans-IV structures (compared to AMD3100) coupled with the versatility in substitution to tune the molecular properties, opens the door to a new sub-class of compounds that may exhibit increased drug efficacy and improved properties as potential CXCR4-targeted anti-cancer agents. This evidence concerns the gene CXCR4 and cancer.